213 related articles for article (PubMed ID: 11748734)
1. Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients.
Winogrodzka A; Wagenaar RC; Bergmans P; Vellinga A; Booij J; van Royen EA; van Emmerik RE; Stoof JC; Wolters EC
Mov Disord; 2001 Nov; 16(6):1033-40. PubMed ID: 11748734
[TBL] [Abstract][Full Text] [Related]
2. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake.
Benamer HT; Patterson J; Wyper DJ; Hadley DM; Macphee GJ; Grosset DG
Mov Disord; 2000 Jul; 15(4):692-8. PubMed ID: 10928580
[TBL] [Abstract][Full Text] [Related]
3. Striatal FP-CIT uptake differs in the subtypes of early Parkinson's disease.
Spiegel J; Hellwig D; Samnick S; Jost W; Möllers MO; Fassbender K; Kirsch CM; Dillmann U
J Neural Transm (Vienna); 2007 Mar; 114(3):331-5. PubMed ID: 16715205
[TBL] [Abstract][Full Text] [Related]
4. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
[TBL] [Abstract][Full Text] [Related]
5. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Pirker W
Mov Disord; 2003 Oct; 18 Suppl 7():S43-51. PubMed ID: 14531046
[TBL] [Abstract][Full Text] [Related]
6. [123I]FP-CIT striatal binding in early Parkinson's disease patients with tremor vs. akinetic-rigid onset.
Isaias IU; Benti R; Cilia R; Canesi M; Marotta G; Gerundini P; Pezzoli G; Antonini A
Neuroreport; 2007 Sep; 18(14):1499-502. PubMed ID: 17712282
[TBL] [Abstract][Full Text] [Related]
7. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity.
Kim SE; Lee WY; Choe YS; Kim JH
Neurol Res; 1999 Apr; 21(3):255-61. PubMed ID: 10319333
[TBL] [Abstract][Full Text] [Related]
8. Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.
Tissingh G; Bergmans P; Booij J; Winogrodzka A; van Royen EA; Stoof JC; Wolters EC
J Neurol; 1998 Jan; 245(1):14-20. PubMed ID: 9457623
[TBL] [Abstract][Full Text] [Related]
9. Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.
Rossi C; Frosini D; Volterrani D; De Feo P; Unti E; Nicoletti V; Kiferle L; Bonuccelli U; Ceravolo R
Eur J Neurol; 2010 Apr; 17(4):626-30. PubMed ID: 20050904
[TBL] [Abstract][Full Text] [Related]
10. An FP-CIT PET comparison of the difference in dopaminergic neuronal loss in subtypes of early Parkinson's disease.
Song IU; Chung YA; Oh JK; Chung SW
Acta Radiol; 2014 Apr; 55(3):366-71. PubMed ID: 23943629
[TBL] [Abstract][Full Text] [Related]
11. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease.
Seibyl JP; Marek KL; Quinlan D; Sheff K; Zoghbi S; Zea-Ponce Y; Baldwin RM; Fussell B; Smith EO; Charney DS; van Dyck C
Ann Neurol; 1995 Oct; 38(4):589-98. PubMed ID: 7574455
[TBL] [Abstract][Full Text] [Related]
12. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
13. Striatal dopamine transporters and cognitive function in Parkinson's disease.
Stögbauer J; Rosar F; Dillmann U; Faßbender K; Ezziddin S; Spiegel J
Acta Neurol Scand; 2020 Oct; 142(4):385-391. PubMed ID: 32914881
[TBL] [Abstract][Full Text] [Related]
14. Impaired finger dexterity and nigrostriatal dopamine loss in Parkinson's disease.
Lee SH; Lee MJ; Lyoo CH; Cho H; Lee MS
J Neural Transm (Vienna); 2018 Sep; 125(9):1333-1339. PubMed ID: 29971496
[TBL] [Abstract][Full Text] [Related]
15. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.
Tissingh G; Booij J; Bergmans P; Winogrodzka A; Janssen AG; van Royen EA; Stoof JC; Wolters EC
J Nucl Med; 1998 Jul; 39(7):1143-8. PubMed ID: 9669384
[TBL] [Abstract][Full Text] [Related]
16. Different patterns of nigrostriatal degeneration in tremor type versus the akinetic-rigid and mixed types of Parkinson's disease at the early stages: molecular imaging with 123I-FP-CIT SPECT.
Schillaci O; Chiaravalloti A; Pierantozzi M; Di Pietro B; Koch G; Bruni C; Stanzione P; Stefani A
Int J Mol Med; 2011 Nov; 28(5):881-6. PubMed ID: 21811760
[TBL] [Abstract][Full Text] [Related]
17. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease.
Gerschlager W; Bencsits G; Pirker W; Bloem BR; Asenbaum S; Prayer D; Zijlmans JC; Hoffmann M; Brücke T
Mov Disord; 2002 May; 17(3):518-23. PubMed ID: 12112200
[TBL] [Abstract][Full Text] [Related]
18. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease.
Asenbaum S; Pirker W; Angelberger P; Bencsits G; Pruckmayer M; Brücke T
J Neural Transm (Vienna); 1998; 105(10-12):1213-28. PubMed ID: 9928890
[TBL] [Abstract][Full Text] [Related]
19. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression.
Marek K; Innis R; van Dyck C; Fussell B; Early M; Eberly S; Oakes D; Seibyl J
Neurology; 2001 Dec; 57(11):2089-94. PubMed ID: 11739831
[TBL] [Abstract][Full Text] [Related]
20. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study.
Pirker W; Djamshidian S; Asenbaum S; Gerschlager W; Tribl G; Hoffmann M; Brücke T
Mov Disord; 2002 Jan; 17(1):45-53. PubMed ID: 11835438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
